Bond.az White LogoBond.az Black Logo
→
EN ▾
AZENRU
Conifex Timber Q1 2026: Loss and ChallengesEstée Lauder nears sale of Too Faced, Smashbox and Dr. Jart brandsHudson Technologies CEO Buys $24,474 in StockHudson Technologies director buys $25,092 in stockDangerous construction in Masazir? - VideoPresidio Production Q1 2026 results after mergerMoltiply Group Q1 2026: Strong Growth Amid ChallengesNW European gasoline margins drop 14%ICU Medical VP Sanzone sells $303,623 in stockXi Jinping accepts Trump's invitationConifex Timber Q1 2026: Loss and ChallengesEstée Lauder nears sale of Too Faced, Smashbox and Dr. Jart brandsHudson Technologies CEO Buys $24,474 in StockHudson Technologies director buys $25,092 in stockDangerous construction in Masazir? - VideoPresidio Production Q1 2026 results after mergerMoltiply Group Q1 2026: Strong Growth Amid ChallengesNW European gasoline margins drop 14%ICU Medical VP Sanzone sells $303,623 in stockXi Jinping accepts Trump's invitation
Personalize
Bond.az White LogoBond.az Black Logo
AZENRU

#ars-pharmaceuticals

Latest news and interesting information about ars-pharmaceuticals.

ARS Pharma Misses Q1 2026 EPS Forecast, Stock Drops
Today / 15:31
|
482

ARS Pharma Misses Q1 2026 EPS Forecast, Stock Drops

ARS Pharma Q1 2026 EPS miss leads to 8.56% stock drop. Neffy prescriptions triple but high costs pressure profits.

TRANSCRIPTS →
0
...